In a Longevity.Technology UNLOCKED interview, Christopher Shade of Quicksilver Scientific argues that absorption and clearance capacity determine whether a supplement produces any effect at all. He describes pharmacokinetic testing in which conventional capsules generated widely variable blood levels between individuals, while liposomal and nanoemulsion delivery produced higher and more consistent exposure. The implication for longevity practice is that identical doses do not constitute identical interventions.
Key Points
- Identical capsule doses produced highly variable blood levels between individuals
- Mobilizing toxins without clearance routes does not remove them
- Improved delivery raises exposure but not necessarily clinical benefit
Longevity Analysis
Compound selection dominates longevity discussion while absorption, transport and clearance capacity determine the actual dose delivered to tissue. Layering interventions onto a system with impaired hepatic, biliary and gastrointestinal clearance wastes the intervention and may increase burden, which places sequencing — clearing interference before adding inputs — ahead of protocol expansion. The pharmacokinetic variability between individuals also argues for measured exposure rather than assumed exposure, particularly as enhanced delivery systems raise blood levels of compounds whose safety margins were established at conventional oral absorption.
Original published by Longevity.Technology, by Kyle Umipig.